KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 72 filers reported holding KINNATE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,261,272 | -53.8% | 2,329,480 | 0.0% | 0.99% | -58.8% |
| Q2 2023 | $7,058,324 | -51.5% | 2,329,480 | 0.0% | 2.40% | -60.5% |
| Q1 2023 | $14,559,250 | +2.5% | 2,329,480 | 0.0% | 6.08% | +7.5% |
| Q4 2022 | $14,209,828 | -55.3% | 2,329,480 | -12.5% | 5.65% | -45.0% |
| Q3 2022 | $31,810,000 | -16.1% | 2,661,888 | -11.5% | 10.27% | -19.7% |
| Q2 2022 | $37,934,000 | +12.0% | 3,008,243 | 0.0% | 12.80% | +32.3% |
| Q1 2022 | $33,873,000 | -36.5% | 3,008,243 | 0.0% | 9.67% | -31.1% |
| Q4 2021 | $53,306,000 | – | 3,008,243 | – | 14.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
| Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
| Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
| Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
| Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
| Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
| RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
| Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |